The Nellcor Bedside SpO2 system includes the company’s OxiMax technology and is designed to continuously monitor SpO2 and pulse rate for adult, pediatric and neonatal patients.
“We are pleased to announce the new Covidien Nellcor Bedside SpO2 Patient Monitoring System is approved for commercial release in the United States,” said Robert White, president, respiratory and monitoring solutions, Covidien, in the release. “Healthcare professionals on the general care floor, and in other lower- acuity areas of the hospital, need critical patient information at their fingertips so they can respond quickly to health threats. By giving them ready access to a patient’s respiratory history, the system allows them to focus on delivering efficient, high-quality care, not gathering and managing data.”
Covidien has its U.S. headquarters in Mansfield, Mass.
Related Articles on FDA Clearances:
Siemens Receives FDA Clearance for MRI System
Roche Receives FDA Clearance for Insulin Pump Therapy System
GE Healthcare Receives FDA Clearance for Cardiac Spectral CT
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.